Birdwatch Note
2024-05-19 03:08:23 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
No, the Ebola clinical trial involving the COVID-19 drug Remdesivir did not show Remdesivir had a 50% mortality rate. This is a false interpretation of the study. The study showed that Ebola infection had a 53% mortality rate. Ebola can have up to a 90% mortality rate https://nejm.org/doi/full/10.1056/nejmoa1910993 https://paho.org/en/topics/ebola-virus-disease
Written by F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1791990248685101323
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1792029505676087796
- noteId - 1792029505676087796
- participantId -
- noteAuthorParticipantId - F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D Participant Details
- createdAtMillis - 1716088103109
- tweetId - 1791990248685101323
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- No, the Ebola clinical trial involving the COVID-19 drug Remdesivir did not show Remdesivir had a 50% mortality rate. This is a false interpretation of the study. The study showed that Ebola infection had a 53% mortality rate. Ebola can have up to a 90% mortality rate https://nejm.org/doi/full/10.1056/nejmoa1910993 https://paho.org/en/topics/ebola-virus-disease
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-05-19 03:08:23 UTC (1716088103109) |
2024-05-19 09:29:27 UTC (1716110967283) |
CURRENTLY_RATED_HELPFUL | 2024-05-20 02:18:08 UTC (1716171488374) |
CURRENTLY_RATED_HELPFUL | 2024-05-19 09:29:27 UTC (1716110967283) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-05-19 13:17:26 -0500 | Rating Details | |
| 2024-05-19 05:30:56 -0500 | Rating Details | |
| 2024-05-19 03:56:15 -0500 | Rating Details | |
| 2024-05-19 03:32:58 -0500 | Rating Details | |
| 2024-05-19 03:07:04 -0500 | Rating Details | |
| 2024-05-19 02:23:58 -0500 | Rating Details | |
| 2024-05-19 01:16:58 -0500 | Rating Details | |
| 2024-05-19 00:49:59 -0500 | Rating Details | |
| 2024-05-19 00:34:31 -0500 | Rating Details | |
| 2024-05-19 00:18:44 -0500 | Rating Details | |
| 2024-05-19 00:09:05 -0500 | Rating Details | |
| 2024-05-19 00:05:55 -0500 | Rating Details | |
| 2024-05-19 00:03:48 -0500 | Rating Details | |
| 2024-05-18 23:20:15 -0500 | Rating Details | |
| 2024-05-18 22:33:57 -0500 | Rating Details | |
| 2024-05-18 22:29:40 -0500 | Rating Details | |
| 2024-05-18 22:27:26 -0500 | Rating Details | |
| 2024-05-18 22:12:28 -0500 | Rating Details | |
| 2024-05-20 11:21:09 -0500 | Rating Details | |
| 2024-05-19 15:23:19 -0500 | Rating Details | |
| 2024-05-19 15:22:51 -0500 | Rating Details | |
| 2024-05-19 11:45:56 -0500 | Rating Details | |
| 2024-05-19 08:03:51 -0500 | Rating Details | |
| 2024-05-19 02:20:59 -0500 | Rating Details | |
| 2024-05-19 01:30:02 -0500 | Rating Details | |
| 2024-05-19 01:18:32 -0500 | Rating Details | |
| 2024-05-19 00:17:11 -0500 | Rating Details | |
| 2024-05-18 23:24:27 -0500 | Rating Details | |
| 2024-05-18 23:17:12 -0500 | Rating Details | |
| 2024-05-18 23:05:48 -0500 | Rating Details | |
| 2024-05-18 23:03:50 -0500 | Rating Details | |
| 2024-05-18 22:40:07 -0500 | Rating Details | |
| 2024-05-18 22:29:57 -0500 | Rating Details | |
| 2024-05-18 22:22:55 -0500 | Rating Details | |
| 2024-05-22 10:31:53 -0500 | Rating Details | |
| 2024-05-21 03:29:02 -0500 | Rating Details | |
| 2024-05-20 13:25:01 -0500 | Rating Details | |
| 2024-05-20 06:34:44 -0500 | Rating Details | |
| 2024-05-19 08:04:39 -0500 | Rating Details | |
| 2024-05-19 02:23:19 -0500 | Rating Details | |
| 2024-05-19 01:57:40 -0500 | Rating Details | |
| 2024-05-19 01:14:13 -0500 | Rating Details | |
| 2024-05-19 00:51:47 -0500 | Rating Details | |
| 2024-05-19 00:44:13 -0500 | Rating Details | |
| 2024-05-19 00:29:13 -0500 | Rating Details | |
| 2024-05-18 22:47:21 -0500 | Rating Details | |
| 2024-05-18 22:38:04 -0500 | Rating Details | |
| 2024-05-18 22:34:39 -0500 | Rating Details | |
| 2024-05-18 22:29:46 -0500 | Rating Details | |
| 2024-05-19 17:34:03 -0500 | Rating Details | |
| 2024-05-29 23:14:57 -0500 | Rating Details | |
| 2024-05-29 20:10:56 -0500 | Rating Details | |
| 2024-05-27 05:17:30 -0500 | Rating Details | |
| 2024-05-20 20:45:01 -0500 | Rating Details | |
| 2024-05-20 11:23:10 -0500 | Rating Details | |
| 2024-05-20 03:23:01 -0500 | Rating Details | |
| 2024-05-19 18:00:51 -0500 | Rating Details | |
| 2024-05-19 10:24:17 -0500 | Rating Details | |
| 2024-05-19 04:57:29 -0500 | Rating Details | |
| 2024-05-19 03:54:34 -0500 | Rating Details | |
| 2024-05-19 01:46:23 -0500 | Rating Details | |
| 2024-05-19 01:26:13 -0500 | Rating Details | |
| 2024-05-19 00:59:08 -0500 | Rating Details | |
| 2024-05-19 00:03:10 -0500 | Rating Details | |
| 2024-05-18 23:17:44 -0500 | Rating Details | |
| 2024-05-18 23:15:12 -0500 | Rating Details | |
| 2024-05-18 22:37:10 -0500 | Rating Details | |
| 2024-05-18 22:30:09 -0500 | Rating Details | |
| 2024-05-20 13:24:59 -0500 | Rating Details | |
| 2024-05-19 15:36:05 -0500 | Rating Details | |
| 2024-07-08 04:57:40 -0500 | Rating Details |